Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL

Inclusion Criteria: According to world Health Organization (WHO) classification of disease, DLBCL was confirmed by histology, relapsed or refractory after first-line treatment, and CR or PR after upfront treatment; 18≤ age ≤65 years old, male or female; Bcl-2 positive rate >50% according to immunohistochemistry of biopsied tissue; No serious organic lesions in the main organs, meeting the requirements of the following laboratory examination indicators (conducted within 7 days before treatment) : White blood cell count ≥3.0×109/L, absolute neutrophil count ≥1.5×109/L, hemoglobin ≥90g/L, platelet ≥75×109/L; Total bilirubin ≤1.5× upper normal value (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5× upper normal value (ULN); Creatinine clearance was 44-133 mmol/L; ECOG score 0-1; The subject or his/her legal representative must provide written informed consent prior to conducting a special study examination or procedure. Exclusion Criteria: Previously received autologous hematopoietic stem cell transplantation; Suffering from serious complications or severe infection; Previously treated with Venetoclax; Central nervous system lymphoma was excluded; Suffering from serious complications or severe infection; A history of other malignant tumors within 5 years, excluding early tumors treated for curative purposes; Patients with uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, serious infectious diseases, etc.; HBsAg, HCV or HIV positive. Positive HBV and HCV serology is allowed, but DNA/RNA testing must be negative; Laboratory test value during screening; Neutrophils <1.5×109/L; Platelet <75×109/L; Bilirubin was 1.5 times higher than the normal upper limit, transaminase was 2.5 times higher than the normal upper limit; The creatinine level is higher than 1.5 times the upper limit of normal value; Left ventricular ejection fraction ≦ 50%; Other concurrent and uncontrolled medical conditions considered by the investigator would affect the patient's participation in the study; Psychiatric patients or other patients known or suspected to be unable to fully comply with the study protocol; Pregnant or lactating women; The researcher judged that the patients were not suitable for this study.